 The use of nanotechnology in medicine has the potential to greatly impact human health through the prevention, diagnosis, and treatment of diseases by designing and developing nanoparticulate nanomedicines, NNMs, for drug delivery via various mechanisms such as solubilization, passive targeting, active targeting, and triggered release. However, several experimental challenges need to be addressed before NNMs can move from the bench to the bedside, including biological challenges, large-scale manufacturing, biocompatibility and safety, intellectual property, government regulations, and overall cost-effectiveness in comparison to current therapies. These factors can limit the appearance of NNMs on the market regardless of their therapeutic benefits. This article was authored by Susan Hoa, Susan Hoa, Maria B. C. DeMottoes, and others.